• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    First Tracks Biotherapeutics, Inc. - Ordinary Shares (NQ:TRAX)

    34.26 +2.41 (+7.57%)
    Delayed Quote Updated: 10:45 AM EDT, Oct 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about First Tracks Biotherapeutics, Inc. - Ordinary Shares

    News headline image
    First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
    From First Tracks Biotherapeutics Inc
    Via GlobeNewswire
    News headline image
    First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
    From First Tracks Biotherapeutics Inc
    Via GlobeNewswire
    News headline image
    First Tracks Biotherapeutics Announces Participation in September Investor Conferences
    From First Tracks Biotherapeutics Inc
    Via GlobeNewswire
    News headline image
    First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
    From First Tracks Biotherapeutics Inc
    Via GlobeNewswire
    News headline image
    First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
    From First Tracks Biotherapeutics Inc
    Via GlobeNewswire
    News headline image
    First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
    From First Tracks Biotherapeutics Inc
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.